Strategic design of extracellular vesicle drug delivery systems.

Extracellular vesicles (EVs), sub-micron vectors used in intercellular communication, have demonstrated great promise as natural drug delivery systems. Recent reports have detailed impressive in vivo results from the administration of EVs pre-loaded with therapeutic cargo, including small molecules, nanoparticles, proteins and oligonucleotides. These results have sparked intensive research interest across a huge range of disease models. There are, however, enduring limitations that have restricted widespread clinical and pharmaceutical adoption. In this perspective, we discuss these practical and biological concerns, critically compare the relative merit of EVs and synthetic drug delivery systems, and highlight the need for a more comprehensive understanding of in vivo transport and delivery. Within this framework, we seek to establish key areas in which EVs can gain a competitive advantage in order to provide the tangible added value required for widespread translation.

[1]  Aled Clayton,et al.  How pure are your vesicles? , 2013, Journal of extracellular vesicles.

[2]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[4]  Molly M Stevens,et al.  Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[6]  F. Menger,et al.  Chemistry and physics of giant vesicles as biomembrane models. , 1998, Current opinion in chemical biology.

[7]  Maria Ericsson,et al.  Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. , 2014, ACS nano.

[8]  J. Urquhart Can drug delivery systems deliver value in the new pharmaceutical marketplace? , 2003, British journal of clinical pharmacology.

[9]  E. Hersh,et al.  Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. , 1984, Cancer research.

[10]  Y. Gupta,et al.  Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. , 2000, Pharmacological research.

[11]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[12]  M. Stevens,et al.  Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy , 2018, Advanced materials.

[13]  P. Robbins,et al.  Regulation of immune responses by extracellular vesicles , 2014, Nature Reviews Immunology.

[14]  M. Epple,et al.  MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease , 2014, Leukemia.

[15]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[16]  T. Anchordoquy,et al.  Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[17]  V. Oberle,et al.  Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils , 2004, Platelets.

[18]  A. Falus,et al.  Emerging role of extracellular vesicles in inflammatory diseases , 2014, Nature Reviews Rheumatology.

[19]  Sameer Jadhav,et al.  Chemistry and Physics of Lipids , 2013 .

[20]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[21]  J. Cooper,et al.  Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice , 2014, Movement disorders : official journal of the Movement Disorder Society.

[22]  I. Sargent,et al.  Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.

[23]  R. Schiffelers,et al.  PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[24]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[25]  Dongmei Sun,et al.  A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Imre Mäger,et al.  Extracellular vesicles: biology and emerging therapeutic opportunities , 2013, Nature Reviews Drug Discovery.

[27]  Young Jik Kwon,et al.  Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[28]  James P K Armstrong,et al.  Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics. , 2017, ACS nano.

[29]  F. Dell’Accio,et al.  Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis , 2015, Science Translational Medicine.

[30]  B. Conley,et al.  Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin , 2004, Cancer Chemotherapy and Pharmacology.

[31]  M. Wood,et al.  Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography , 2017, Scientific Reports.

[32]  Jacco van Rheenen,et al.  In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior , 2015, Cell.

[33]  Pieter Vader,et al.  Extracellular vesicles as drug delivery systems: lessons from the liposome field. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Y. Barenholz,et al.  Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.

[35]  Molly M Stevens,et al.  Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. , 2015, Nano today.

[36]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[37]  J. Dranoff,et al.  Extracellular vesicles carry microRNA‐195 to intrahepatic cholangiocarcinoma and improve survival in a rat model , 2017, Hepatology.

[38]  Hideo Saji,et al.  Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice. , 2015, Journal of pharmaceutical sciences.

[39]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[40]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[41]  Dongmei Sun,et al.  Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  Yechezkel Barenholz,et al.  Liposome application: problems and prospects , 2001 .

[43]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[44]  W. Faigle,et al.  Cells release prions in association with exosomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[46]  Andrew F. Hill,et al.  Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper , 2015, Journal of extracellular vesicles.

[47]  Imre Mäger,et al.  Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting , 2015, Journal of extracellular vesicles.

[48]  James Pk Armstrong,et al.  Strategies for cell membrane functionalization , 2016, Experimental biology and medicine.

[49]  Jos Malda,et al.  Extracellular vesicles — new tool for joint repair and regeneration , 2016, Nature Reviews Rheumatology.

[50]  Yusuke Yoshioka,et al.  Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier , 2015, Nature Communications.

[51]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[52]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[53]  A. Ulrich Biophysical Aspects of Using Liposomes as Delivery Vehicles , 2002, Bioscience reports.

[54]  Aled Clayton,et al.  Antigen‐presenting cell exosomes are protected from complement‐mediated lysis by expression of CD55 and CD59 , 2003, European journal of immunology.

[55]  M. Bureau,et al.  Magnetic and photoresponsive theranosomes: translating cell-released vesicles into smart nanovectors for cancer therapy. , 2013, ACS nano.

[56]  M. Wood,et al.  Exosomes and the blood-brain barrier: implications for neurological diseases. , 2011, Therapeutic delivery.

[57]  Mehmet Fatih Bolukbasi,et al.  Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Richa Gupta,et al.  Exosomes as drug delivery vehicles for Parkinson's disease therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Myung Soo Kim,et al.  Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[60]  M. Chopp,et al.  MiR‐133b Promotes Neural Plasticity and Functional Recovery After Treatment of Stroke with Multipotent Mesenchymal Stromal Cells in Rats Via Transfer of Exosome‐Enriched Extracellular Particles , 2013, Stem cells.

[61]  Dong Wei,et al.  Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer , 2008, Molecular Therapy.

[62]  A. Guha,et al.  Extracellular vesicles – vehicles that spread cancer genes , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[63]  Yuki Takahashi,et al.  Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. , 2013, Journal of biotechnology.

[64]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[65]  Olivier Lantz,et al.  Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC , 2015, Oncoimmunology.

[66]  Guimei Zhang,et al.  Delivery of chemotherapeutic drugs in tumour cell-derived microparticles , 2012, Nature Communications.